Monday, July 14, 2025

Creating liberating content

Elon musk and the xAI logo. Vincent Feuray | Afp

Not commonly used, Vitamin D injections send the nutrient directly

Related News

Elon musk and the xAI logo. Vincent Feuray | Afp | Getty Images Elon Musk on Monday said he does not support a merger between xAI and Tesla, as questions

Olympic bronze medalist and former world no. 1 badminton player Saina Nehwal has confirmed her separation from her husband and fellow shuttler Parupalli Kashyap after their seven-year-long marriage. The news

Not commonly used, Vitamin D injections send the nutrient directly to the bloodstream. Doctors provide these injections to patients, either on a monthly basis or as required. The most suitable

The WPI inflation had registered at 0.39 per cent in May, whilst it stood at 3.43 per cent in June last year. (AI image) India’s Wholesale Price Index (WPI) inflation

Gibran raises $2.6 million to build nature-inspired, adaptive AI systems (Representative AI image) BENGALURU: AI research startup Gibran has raised $2.6 million in a seed round led by Together Fund

Gold price prediction: Focus this week will be on inflation data from major economies and US PPI, retail sales and industrial production. (AI image) Gold price prediction today: US President

Trending News

Top stocks to buy (AI image) Stock market recommendations: According to Motilal Oswal Financial Services Ltd, the top stock picks for the week (starting July 14, 2025) are Suzlon, and

Bitcoin surged past the $120,000 mark for the first time on Monday, setting a new record as optimism grows over potential regulatory clarity in the US.Bitcoin reached a new all-time

Market experts indicate that ongoing uncertainty in trade talks could maintain markets in a consolidative phase. (AI image) Stock market today: Nifty50 and BSE Sensex, the Indian equity benchmark indices,

NEW DELHI: In an event-heavy week, stock investors will track quarterly earnings of several bluechip firms, likely outcome of ongoing India-US trade talks, and inflation data for market cues, analysts

NEW DELHI: Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra said in the company’s annual report for

SpaceX has committed $2 billion to xAI as part of a $5 billion equity round, deepening the ties between tech billionaire Elon Musk’s ventures as his artificial intelligence startup races

Dr Reddy’s receives two USFDA observations for New York API facility

Word Count: 726 | Estimated Reading Time: 4 minutes


Dr Reddy's receives two USFDA observations for New York API facility

Dr Reddy’s Laboratories announced on Saturday that the United States Food and Drug Administration (USFDA) has issued a Form 483 with two observations following an inspection of its API (Active Pharmaceutical Ingredients) manufacturing facility in Middleburgh, New York.In a regulatory filing, the Hyderabad-based pharmaceutical company stated that the GMP (Good Manufacturing Practice) inspection was carried out between May 12 and May 16, 2025, news agency PTI reported.“At the conclusion of the inspection, we received a Form 483 with two observations, which we will address within the stipulated timeline,” the company said.According to the USFDA, a Form 483 is issued when inspectors identify conditions that may potentially violate the Food, Drug, and Cosmetic (FD&C) Act or related regulations. The observations are shared with a firm’s management to prompt corrective action.On May 16, Dr Reddy’s Laboratories Ltd closed at Rs 1,228.50, marking a decline of Rs 7.80 or 0.63% from the previous trading session. Earlier on Friday, Dr Reddy’s Laboratories had reported a 21 per cent year-on-year increase in consolidated net profit to Rs 1,587 crore for the quarter ended March 2025, driven by strong sales across key markets such as the US and India. The Hyderabad-based pharmaceutical company had recorded a net profit of Rs 1,307 crore in the same quarter of the previous year. Revenue for the January–March quarter had risen to Rs 8,506 crore, compared to Rs 7,083 crore a year earlier, according to a regulatory filing. For the full financial year 2024–25, Dr Reddy’s had posted a net profit of Rs 5,724 crore, marking a modest 3 per cent growth over the Rs 5,568 crore reported in FY24. The company’s annual revenue had increased to Rs 32,553 crore from Rs 27,916 crore in the preceding fiscal.India’s Pharma sectorIndia’s pharmaceutical industry, a major supplier to the United States, is likely to come under increasing pressure amid heightened regulatory scrutiny. In FY24, the US accounted for $8.7 billion of India’s total pharma exports of $27.9 billion, according to the Pharmaceuticals Export Promotion Council of India. More than 45% of the generic drugs used in the US are manufactured in India, underscoring the country’s crucial role in the American healthcare system, according to an ET report. Additionally, Indian firms supply approximately 15% of the biosimilars consumed in the US. Leading companies such as Sun Pharma, Dr Reddy’s, Aurobindo Pharma, Zydus Lifesciences, and Gland Pharma generate up to half of their revenues from the US market, making them particularly sensitive to regulatory developments.





Source link

Most Popular Articles

Sign In

Welcome ! Log into Your Account